NCT01739660View on ClinicalTrials.gov

Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Chronic Kidney Disease Stage 5
Interventions
DRUG

Pegloticase

a single 8 mg iv (in the vein) dose before hemodialysis session

Trial Locations (1)

55404

Davita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Savient Pharmaceuticals

INDUSTRY